All lobbying filings

Definium Therapeutics (FKA Mind Medicine (Mindmed) Inc.)

Definium Therapeutics (FKA Mind Medicine (Mindmed) Inc.) filed a Q4 report for Definium Therapeutics (FKA Mind Medicine (Mindmed) Inc.) on January 20, 2026.

Lobbying for Definium Therapeutics (FKA Mind Medicine (Mindmed) Inc.) · Biopharmaceutical organization developing medicines for disorders of the brain.

As filed: DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.) for DEFINIUM THERAPEUTICS (FKA MIND MEDICINE (MINDMED) INC.).

All filings by Definium Therapeutics (FKA Mind Medicine (Mindmed) Inc.) · Everything Definium Therapeutics (FKA Mind Medicine (Mindmed) Inc.) has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$90,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Maryland

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Lack of innovation in mental health. Need for more efficient communication/collaboration between FDA/DEA and need for VA to operationalize itself for when new therapies are approved by the FDA and rescheduled by the DEA.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.